Clinical Trial Update: Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing alisertib plus paclitaxel versus paclitaxel alone in metastatic or locally recurrent breast cancer. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Alisertib (alisertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: US Oncology Research | Conditions: Breast Cancer, Breast Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-10-09